
Daniel T. McKillop
Partner
201-896-7115 dmckillop@sh-law.comFirm Insights
Author: Daniel T. McKillop
Date: August 18, 2017

Partner
201-896-7115 dmckillop@sh-law.comA former NFL player, two children, and an Iraq War veteran suffering from post-traumatic stress disorder, all of whom are medical marijuana patients, together with a social justice nonprofit organization recently filed a federal lawsuit asserting that marijuana’s status as a “Schedule I” narcotic under the Controlled Substances Act (CSA) is so irrational that it violates the U.S. Constitution. The defendants in the case are Attorney General Jeff Sessions, Acting DEA Administrator Charles Rosenberg, the U.S. Justice Department, the DEA and the federal government.

The landmark lawsuit alleges that the federal government’s classification of marijuana was never supported by strong scientific/medical evidence. To be classified under Schedule I, a drug: (i) must have a high potential for abuse; (ii) must have absolutely no medical use in treatment; and (iii) cannot be used or tested safely, even under strict medical supervision.
As highlighted in the suit, a government commission convened in the 1970s under President Richard Nixon recommended that marijuana use should not be criminal or subject someone to an indictment based on its findings that it posed very little risk to the public. “Looking only at the effects on the individual, there, is little-proven danger of physical or psychological harm from the experimental or intermittent use of the natural preparations of cannabis,” the report stated. Nonetheless, President Nixon adopted his own approach, declaring all drug abuse as “public enemy number one in the United States.”
According to the complaint, “The Nixon Administration ushered the CSA through Congress and insisted that cannabis be included on Schedule I so that African Americans and war protesters could be raided, prosecuted and incarcerated without identifying the actual and unconstitutional basis for the government’s actions.”
The lawsuit argues that classifying marijuana as a Class I drug is even more “irrational” today. “Indeed, the Federal Government has admitted repeatedly in writing and implemented national policy reflecting that Cannabis does in fact, have medical uses and can be used and tested safely under medical supervision,” the complaint states. “On that basis, the federal government has exploited cannabis economically for more than a decade by securing a medical cannabis patent and entering into license agreements with medical licensees.”
The suit further contends that the federal government’s refusal to revisit the classification is harming medical marijuana patients and businesses seeking to serve them. One of the plaintiffs is former Dallas Cowboys defensive end Marvin Washington. He is challenging the CSA because it prevents him from obtaining grants under the Federal Minority Business Enterprise program to start a medical marijuana company. Other plaintiffs who are medical marijuana patients maintain that federal criminalization prohibits them from traveling freely by airplane or to states where medical cannabis is illegal, and the Cannabis Cultural Association argues that CSA was enacted and continues to be enforced in a discriminatory manner and prevents minorities from participating in the legal cannabis industry.
If the plaintiffs prevail, the decision would not repeal the CSA but would result in a permanent injunction against enforcement of the CSA with respect to marijuana. The case is venued in the U.S. District Court for the Southern District of New York, Docket No. 1:17-cv-05625. Medical marijuana patients and cannabis industry members should stay apprised of related developments.
This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:
If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, at 201-806-3364.
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Commercial real estate trends in 2026 are being shaped by shifting economic conditions, technological innovation, and evolving tenant demands. As the market adjusts to changing interest rates, capital flows, and workplace models, investors, owners, tenants, and developers must understand how these trends are influencing opportunities and risk in the year ahead. Overall Outlook for Commercial […]
Author: Michael J. Willner

Part 2 – Tips Excluded from Income Certain employees and independent contractors may be eligible to deduct tips from their income for tax years 2025 through 2028 under provisions included in the One Big Beautiful Bill. The deduction is capped at $25,000 per year and begins to phase out at $150,000 of modified adjusted gross […]
Author: Scott H. Novak

Part 1 – Overtime Pay and Income Tax Treatment Overview This Firm Insights post summarizes one provision of the “One Big Beautiful Bill” related to the tax treatment of overtime compensation and related employer wage reporting obligations. Overtime Pay and Employee Tax Treatment The Fair Labor Standards Act (FLSA) generally requires that overtime be paid […]
Author: Scott H. Novak

In 2025, New York enacted one of the most consequential updates to its consumer protection framework in decades. The Fostering Affordability and Integrity through Reasonable Business Practices Act (FAIR Act) significantly expands the scope and strength of New York’s long-standing consumer protection statute, General Business Law § 349, and alters the compliance landscape for New York […]
Author: Dan Brecher

For many New Jersey businesses, growth is a primary objective for the New Year. However, it is important to recognize that growth involves both opportunity and risk. For example, business expansion often results in complex contracts, an increased workforce, new regulatory requirements, and heightened exposure to disputes. Without proactive planning, even routine growth can lead […]
Author: Ken Hollenbeck

Crypto investor protection continues to evolve, with the SEC and CFTC investing resources and coordinating more closely to uphold regulatory standards. Whether you’re a retail investor, an institutional trader, or part of a crypto startup, understanding enforcement trends is essential for navigating this dynamic and high-stakes regulatory environment. Crypto Is No Longer the Wild West […]
Author: Dan Brecher
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!